Skip to main content
SpringerLink
Log in

Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer

  • Letter to the Editor
  • Published:
Gastric Cancer Aims and scope Submit manuscript

The Original Article was published on 21 November 2023

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yoshikawa T, Terashima M, Mizusawa J, et al. 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer. Gastric Cancer. 2024;27:155–63. https://doi.org/10.1007/s10120-023-01447-5.

    Article  CAS  PubMed  Google Scholar 

  2. Yoshikawa T, Terashima M, Mizusawa J, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019;4:208–16. https://doi.org/10.1016/s2468-1253(18)30383-2.

    Article  PubMed  Google Scholar 

  3. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4:363–71. https://doi.org/10.1161/circoutcomes.110.957951.

    Article  PubMed  Google Scholar 

  4. Kim HS, Kang J, Hwang D, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020;396:1079–89. https://doi.org/10.1016/s0140-6736(20)31791-8.

    Article  CAS  PubMed  Google Scholar 

  5. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20. https://doi.org/10.1056/NEJMoa072252.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-Gil, Songpa-gu, Seoul, 05505, Republic of Korea

    Hyung-Don Kim, Min-Hee Ryu & Yoon-Koo Kang

  2. Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Seoul, South Korea

    Ji Sung Lee

Authors
  1. Hyung-Don Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min-Hee Ryu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ji Sung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoon-Koo Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoon-Koo Kang.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, HD., Ryu, MH., Lee, J.S. et al. Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer. Gastric Cancer (2024). https://doi.org/10.1007/s10120-024-01496-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10120-024-01496-4

Search

Navigation